Barinthus Biotherapeutics Plc ADR (BRNS)

$1.04 +0.03 (2.97%)
Market Cap 41.84M
Revenue (ttm) 800,000.00
Net Income (ttm) -73.35M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -9,168.75%
Debt to Equity Ratio 0.00
Volume 24,300
Avg Vol 57,142
Day's Range N/A - N/A
Shares Out 40.23M
Stochastic %K 35%
Beta -0.81
Analysts Strong Sell
Price Target $6.50

Latest News on BRNS

Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update

Jan 10, 2025, 8:00 AM EST - 8 days ago

Barinthus Bio Announces Strategic Focus in Immunology and Inflammation (I&I) and Provides a Financial Update

Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer

Nov 25, 2024, 4:01 PM EST - 7 weeks ago

Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

Nov 15, 2024, 11:02 AM EST - 2 months ago

Barinthus Bio Announces Results From Ongoing Phase 2b Chronic Hepatitis B Trial, Including Achievement of Functional Cure and HBsAb Seroconversion

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Nov 15, 2024, 11:01 AM EST - 2 months ago

Arbutus and Barinthus Bio Announce New Data from the IM-PROVE II Trial Showing that the Addition of Nivolumab Increased Rates of HBsAg Loss in People with Chronic Hepatitis B

Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results

Nov 6, 2024, 8:00 AM EST - 2 months ago

Barinthus Bio Reports Third Quarter 2024 Update on Corporate Developments and Financial Results

Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections

Jun 12, 2024, 4:01 PM EDT - 7 months ago

Barinthus Bio Announces Strategic Pipeline Prioritization Following Positive Interim Data from VTP-300 in Chronic Hepatitis B Virus Infections

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

Jun 6, 2024, 11:15 AM EDT - 8 months ago

Barinthus Bio's VTP-300 Trials Demonstrate Ability to Achieve Undetectable HBsAg levels and Statistical Significance in Lowering HBsAg Levels in People with Chronic Hepatitis B

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments

May 13, 2024, 8:00 AM EDT - 8 months ago

Barinthus Bio Reports First Quarter 2024 Financial Results and Update on Corporate Developments

Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer

May 1, 2024, 7:00 AM EDT - 9 months ago

Barinthus Bio Names Experienced Physician, Leon Hooftman, M.D., as Chief Medical Officer

Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

Apr 18, 2024, 4:10 PM EDT - 9 months ago

Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections

Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments

Mar 20, 2024, 8:15 AM EDT - 10 months ago

Barinthus Bio Reports Full Year 2023 Financial Results and Update on Corporate Developments

Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

Jan 5, 2024, 4:01 PM EST - 1 year ago

Barinthus Bio Provides a Financial Update and Announces Anticipated 2024 Corporate Milestones

New partnership aims to advance vaccine against MERS coronavirus

Dec 21, 2023, 7:31 AM EST - 1 year ago

New partnership aims to advance vaccine against MERS coronavirus

Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD

Nov 9, 2023, 4:24 PM EST - 1 year ago

Barinthus Bio Presents Interim Data from Phase 2b HBV003 Trial and Phase 2a AB-729-202 Trial in Collaboration with Arbutus Biopharma in Chronic HBV Patients at AASLD

Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

Nov 9, 2023, 4:01 PM EST - 1 year ago

Barinthus Bio Reports Third Quarter 2023 Financial Results and Recent Corporate Developments

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

Nov 6, 2023, 9:05 AM EST - 1 year ago

Vaccitech Renames as Barinthus Biotherapeutics to Highlight Strategic Evolution into a T Cell Immunotherapy Company Targeting Chronic Infectious Diseases, Autoimmunity, and Cancer

Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

Sep 13, 2023, 8:00 AM EDT - 1 year ago

Vaccitech to Host KOL Webinar on Seeking a Functional Cure for Chronic Hepatitis B on September 20, 2023

Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

Aug 10, 2023, 8:00 AM EDT - 1 year ago

Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate Developments

Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B

Jun 21, 2023, 9:03 AM EDT - 1 year ago

Vaccitech to Present Positive Final Data at EASL Congress for Phase 1b/2 HBV002 Study in Adults with Chronic Hepatitis B

Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy

Jun 12, 2023, 7:30 AM EDT - 1 year ago

Vaccitech Doses First Patient in PCA001, a Prostate Cancer Phase 1/2 Clinical Trial of VTP-850 Immunotherapeutic Candidate in Men with Rising PSA after Definitive Local Therapy

Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments

May 12, 2023, 8:00 AM EDT - 1 year ago

Vaccitech Reports First Quarter 2023 Financial Results and Recent Corporate Developments

Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B

Mar 28, 2023, 8:00 AM EDT - 1 year ago

Vaccitech Announces Positive Topline Final Data for HBV002 Study in People with Chronic Hepatitis B

Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

Mar 24, 2023, 8:06 AM EDT - 1 year ago

Vaccitech Reports Full-Year 2022 Financial Results and an Update on Corporate Developments

Vaccitech to Host KOL Webinar on the SNAPvax™ Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases

Nov 21, 2022, 10:31 AM EST - 2 years ago

Vaccitech to Host KOL Webinar on the SNAPvax™ Platform for Inducing Tolerance to Treat Celiac and other Autoimmune Diseases

Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

Nov 10, 2022, 4:30 PM EST - 2 years ago

Vaccitech Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

Vaccitech Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis B

Nov 7, 2022, 8:00 AM EST - 2 years ago

Vaccitech Provides Update on Ongoing VTP-300 Phase 1b/2a Trial Showing Sustained Reductions of HBsAg in Patients with Chronic Hepatitis B

Vaccitech Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® Providing Update on the Phase 1b/2a Study of VTP-300

Nov 2, 2022, 8:00 AM EDT - 2 years ago

Vaccitech Announces Late-Breaker Abstract Accepted for Presentation at AASLD - The Liver Meeting® Providing Update on the Phase 1b/2a Study of VTP-300

Vaccitech to Present at Upcoming October Investor & Scientific Conferences

Oct 3, 2022, 4:30 PM EDT - 2 years ago

Vaccitech to Present at Upcoming October Investor & Scientific Conferences

Vaccitech Promotes Gemma Brown as Chief Financial Officer

Sep 20, 2022, 4:30 PM EDT - 2 years ago

Vaccitech Promotes Gemma Brown as Chief Financial Officer

Vaccitech to Present at Upcoming September Investors Conferences

Sep 7, 2022, 4:01 PM EDT - 2 years ago

Vaccitech to Present at Upcoming September Investors Conferences

Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

Aug 9, 2022, 4:15 PM EDT - 2 years ago

Vaccitech Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

Vaccitech to Present at the William Blair Biotech Focus Conference 2022

Jul 7, 2022, 4:15 PM EDT - 2 years ago

Vaccitech to Present at the William Blair Biotech Focus Conference 2022

Vaccitech's Vaccine Induced Sustained Reductions In Hepatitis B Associated Antigens

Jun 22, 2022, 1:48 PM EDT - 2 years ago

Vaccitech's Vaccine Induced Sustained Reductions In Hepatitis B Associated Antigens

Vaccitech's VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1

Jun 22, 2022, 6:00 AM EDT - 2 years ago

Vaccitech's VTP-300 induced sustained reductions of surface antigen in patients with chronic hepatitis B both as a monotherapy and in combination with a single low dose of anti-PD-1

Vaccitech to Present at the Jefferies Healthcare Conference

Jun 6, 2022, 4:15 PM EDT - 2 years ago

Vaccitech to Present at the Jefferies Healthcare Conference

Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

Jun 6, 2022, 7:32 AM EDT - 2 years ago

Arbutus and Vaccitech Dose First Patient in Phase 2a Clinical Trial Combining Therapies for the Treatment of Chronic Hepatitis B Virus

Vaccitech to Present at the H.C. Wainwright Global Investment Conference

May 20, 2022, 11:30 AM EDT - 2 years ago

Vaccitech to Present at the H.C. Wainwright Global Investment Conference

Vaccitech Reports First Quarter 2022 Financial Results and Recent Corporate Developments

May 11, 2022, 4:15 PM EDT - 2 years ago

Vaccitech Reports First Quarter 2022 Financial Results and Recent Corporate Developments

Vaccitech Announces Notification of Milestone and Royalty Revenue Relating to Sales of Vaxzevria®

Apr 6, 2022, 4:15 PM EDT - 3 years ago

Vaccitech Announces Notification of Milestone and Royalty Revenue Relating to Sales of Vaxzevria®

Vaccitech: Aiming For A Cure In Chronic Hepatitis B

Apr 3, 2022, 7:57 PM EDT - 3 years ago

Vaccitech: Aiming For A Cure In Chronic Hepatitis B

Vaccitech Reports Full-Year 2021 Financial Results and Recent Corporate Developments

Mar 25, 2022, 7:15 AM EDT - 3 years ago

Vaccitech Reports Full-Year 2021 Financial Results and Recent Corporate Developments

Vaccitech to Present at the Barclays Global Healthcare Conference 2022

Mar 7, 2022, 8:00 AM EST - 3 years ago

Vaccitech to Present at the Barclays Global Healthcare Conference 2022

Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine

Jan 18, 2022, 3:00 AM EST - 3 years ago

Cancer Research UK Dose First Patient in Phase I/IIa Trial of Lung Cancer Immunotherapy Vaccine

Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics Landscape

Jan 13, 2022, 4:34 PM EST - 3 years ago

Vaccitech to Host Virtual KOL Event on VTP-300, a Potential Functional Cure for Chronic Hepatitis B (CHB) Infection, and the Broader CHB Therapeutics Landscape

Vaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines

Dec 13, 2021, 4:05 PM EST - 3 years ago

Vaccitech acquires Avidea Technologies to expand product pipeline and strengthen scientific leadership in immunotherapies and vaccines

Vaccitech Posts Interim Efficacy Data From Early-Stage Hepatitis B Trial

Dec 7, 2021, 9:49 AM EST - 3 years ago

Vaccitech Posts Interim Efficacy Data From Early-Stage Hepatitis B Trial

Vaccitech to Participate at The 33rd Annual Virtual Piper Sandler Healthcare Conference

Nov 24, 2021, 9:20 AM EST - 3 years ago

Vaccitech to Participate at The 33rd Annual Virtual Piper Sandler Healthcare Conference

Vaccitech Reports Third Quarter 2021 Financial Results and Recent Corporate Developments

Nov 12, 2021, 7:00 AM EST - 3 years ago

Vaccitech Reports Third Quarter 2021 Financial Results and Recent Corporate Developments

Vaccitech Announces Publication of Second Phase 1 Clinical Trial Results of ChAdOx1 Vaccine in Development for the MERS Coronavirus

Nov 4, 2021, 4:00 AM EDT - 3 years ago

Vaccitech Announces Publication of Second Phase 1 Clinical Trial Results of ChAdOx1 Vaccine in Development for the MERS Coronavirus

Vaccitech Reports Second Quarter 2021 Financial Results and Recent Corporate Developments

Aug 12, 2021, 8:00 AM EDT - 3 years ago

Vaccitech Reports Second Quarter 2021 Financial Results and Recent Corporate Developments